RNS Number : 5264E Renalytix PLC 30 June 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. Renalytix plc ("Renalytix" or the "Company") FDA Approves KidneyIntelX.dkd™ FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline
RNS Number : 7716C Renalytix PLC 15 June 2023 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences Four new data presentations, including late breaking clinical study data,
RNS Number : 1817C Renalytix PLC 09 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023 LONDON and SALT LAKE CITY , June 9, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
RNS Number : 1562C Renalytix PLC 08 June 2023 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and SALT LAKE CITY , June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting (" GM ") held earlier today all resolutions
RNS Number : 5700B Renalytix PLC 05 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 LONDON and SALT LAKE CITY , June 5, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter
RNS Number : 5773A Renalytix PLC 25 May 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes Model expected to accelerate deployment of
RNS Number : 1093A Renalytix PLC 22 May 2023 Renalytix plc ("Renalytix" or the "Company") Expansion of insurance coverage for KidneyIntelX TM LONDON and SALT LAKE CITY , May 22, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) reports the expansion of insurance coverage for KidneyIntelX with
RNS Number : 0238Z Renalytix PLC 11 May 2023 Renalytix plc ("Renalytix" or the "Company") Notice of General Meeting and Posting of Circular LONDON and SALT LAKE CITY , May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General
RNS Number : 6476W Renalytix PLC 19 April 2023 Renalytix plc ("Renalytix" or the "Company") New Published Real-World Evidence Shows KidneyIntelX™ Utility Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple
RNS Number : 8895V Renalytix PLC 12 April 2023 Renalytix plc ("Renalytix" or the "Company") Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting In a clinical decision effectiveness study, KidneyIntelX